for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Hubei Jumpcan Pharmaceutical Co Ltd

600566.SS

Latest Trade

27.65CNY

Change

0.13(+0.47%)

Volume

3,695,876

Today's Range

27.47

 - 

27.86

52 Week Range

26.98

 - 

42.38

As of on the Shanghai Stock Exchange ∙ Minimum 15 minute delay

Pricing

Previous Close
27.52
Open
27.51
Volume
3,695,876
3M AVG Volume
107.20
Today's High
27.86
Today's Low
27.47
52 Week High
42.38
52 Week Low
26.98
Shares Out (MIL)
814.92
Market Cap (MIL)
22,532.60
Forward P/E
11.06
Dividend (Yield %)
4.45

Next Event

Q3 2019 Hubei Jumpcan Pharmaceutical Co Ltd Earnings Release

Latest Developments

More

Hubei Jumpcan Pharma's H1 Net Profit Up 14.4% Y/Y

Hubei Jumpcan Pharmaceutical's Net Profit Up in Q1 And 2018 Y/Y

Hubei Jumpcan Pharmaceutical's 9-Month Net Profit Up 44.25 Pct Y/Y

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Hubei Jumpcan Pharmaceutical Co Ltd

HUBEI JUMPCAN PHARMACEUTICAL CO., LTD., formerly Hubei Hongcheng General Machinery Co., Ltd., is a China-based company, principally engaged in the research and development, production and distribution of pharmaceuticals. The Company's products include heat-clearing and detoxifying series, digestive system series, pediatric series, breathing series, cardiovascular series and gynecology series. Its pharmaceuticals consist of tablets, mixtures, injections, capsules, granules and sprays, among others. The Company mainly distributes its products within domestic markets.

Industry

Biotechnology & Drugs

Contact Info

Baotawan, Daqing West Road, Taixing City

+86.523.89719161

http://www.jumpcan.com/

Executive Leadership

Longxiang Cao

Chairman of the Board, General Manager

Hongliang Wu

Chief Financial Officer, Secretary of the Board

Yanshi Deng

Chief Accounting Officer, Director

Yanliang Zhang

Deputy General Manager

Yishuang Zhou

Deputy General Manager

Key Stats

1.67 mean rating - 3 analysts
Sell
Hold
Buy
Revenue (MM, CNY)

2016

4.7K

2017

5.6K

2018

7.2K

2019(E)

8.6K
EPS (CNY)

2016

1.169

2017

1.510

2018

2.070

2019(E)

2.500
Price To Earnings (TTM)
12.48
Price To Sales (TTM)
3.08
Price To Book (MRQ)
4.13
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
13.73
LT Debt To Equity (MRQ)
10.30
Return on Investment (TTM)
31.76
Return on Equity (TTM)
24.04

Latest News

Latest News

BRIEF-Hubei Jumpcan Pharmaceutical unit obtains high-tech enterprise recognition and to enjoy tax preference

* Says its wholly owned subsidiary was recognized as high-tech enterprise again, and to enjoy a tax preference of 15 percent for three years from 2017 to 2019

BRIEF-Hubei Jumpcan Pharmaceutical unit receives GMP certificate

* Says wholly owned pharmaceutical unit received goods manufacture practice (GMP) certificate from Shaanxi Food and Drug Administration

BRIEF-Hubei Jumpcan Pharmaceutical unit receives GMP certificate

* Says its wholly owned unit received goods manufacture practice (GMP) certificate from Jiangsu Food and Drug Administration

BRIEF-Hubei Jumpcan Pharmaceutical issues 843.2 mln yuan convertible corporate bonds

* Says it issued 843.2 million yuan convertible corporate bonds

BRIEF-Hubei Jumpcan Pharmaceutical to issue 843.2 mln yuan convertible bonds

* Says to issue 843.2 million yuan ($127.28 million) convertible bonds

BRIEF-Hubei Jumpcan Ppharmaceutical's 9-month net profit up 34.2 pct y/y

* Says 9-month net profit up 34.2 percent y/y at 907.3 million yuan ($137.77 million)

BRIEF-Hubei Jumpcan Pharma gets regulatory approval to issue bonds

* Says it gets securities regulator's approval to issue 843.2 million yuan ($127.88 million) convertible bonds

BRIEF-Hubei Jumpcan Pharmaceutical gets regulatory approval to issue convertible bonds

* Says it gets securities regulator's approval to issue convertible bonds

BRIEF-Hubei Jumpcan Pharmaceutical cuts convertible bond issue size to up to 843.2 mln yuan

* Says it cuts convertible bond issue size to up to 843.2 million yuan from up to 860 million yuan

BRIEF-Hubei Jumpcan Pharmaceutical's H1 net profit up 32.1 pct y/y

* Says h1 net profit up 32.1 percent y/y at 581.8 million yuan ($86.38 million)

BRIEF-Hubei Jumpcan Pharma to issue up to 860 mln yuan convertible bonds

* Says it plans to issue up to 860 million yuan ($124.55 million) convertible bonds

BRIEF-Regulator halts review of Hubei Jumpcan Pharmaceutical's convertible bond issue plan

* Says securities regulator halts review of its convertible bond issue proposal

BRIEF-Hubei Jumpcan Pharma's Q1 net profit up 39.0 pct y/y

* Says q1 net profit up 39.0 percent y/y at 290.7 million yuan ($42.17 million)

BRIEF-Hubei Jumpcan Pharmaceutical to pay A shares annual div for FY 2016 on April 28

* Says it will pay cash dividend of 0.73 yuan(before tax)/share for 2016 to shareholders of record on April 27

BRIEF-Hubei Jumpcan Pharmaceutical to pay annual cash div as 7.3 yuan per 10 shares for FY 2016

* Says it plans to pay annual cash dividend as 7.3 yuan per 10 shares as FY 2016 div payment

BRIEF-Hubei Jumpcan Pharmaceutical names new chairman, general manger and CFO

* Says it appoints Cao Longxiang as new chairman of the board and general manager, and Wu Hongliang as CFO

BRIEF-Hubei Jumpcan Pharma's prelim 2016 profit rises 35.8 pct y/y

* Says prelim 2016 net profit up 35.8 percent y/y at 932.46 million yuan ($135.91 million)

BRIEF-Hubei Jumpcan Pharmaceutical unit gets GMP certificate

* Says its unit received goods manufacture practice (GMP) certificate from Jiangsu Food and Drug Administration Bureau

BRIEF-Hubei Jumpcan Pharma's 9-mth net profit up, plans to issue convertible bonds

* Says it plans to issue up to 975 million yuan ($144.19 million) convertible bonds

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up